文献速递神经肿瘤

平足蛋白表达是预后生物标志物但可能对胶质母细胞瘤的恶性行为并非必需

Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.
PubMed 文献 · Neuro Oncol · 2019-01-01

本研究在临床前小鼠模型中功能性地研究了平足蛋白对胶质母细胞瘤的影响,以评估其作为治疗靶点的潜力。结果显示,肿瘤进展不依赖于平足蛋白,因此阻断平足蛋白并非有前景的治疗方法,但平足蛋白可作为预后不良的生物标志物。

要点

  • 平足蛋白高表达与胶质母细胞瘤患者预后不良相关
  • 在临床前小鼠模型中,敲除平足蛋白不影响肿瘤生长或生存
  • 平足蛋白可作为预后生物标志物,但阻断它并非有前景的治疗方法

核心结论

  • 肿瘤进展不依赖于平足蛋白,因此与先前建议相反,阻断平足蛋白并非有前景的治疗方法;但平足蛋白与肿瘤侵袭性和进展相关,作者提出该细胞表面蛋白可作为预后不良的生物标志物。

研究设计与样本

  • 临床前小鼠模型研究,结合荧光激活细胞分选、全基因组表达分析、CRISPR/Cas9介导的平足蛋白敲除(在患者来源的人胶质母细胞瘤细胞中)、器官型脑切片培养和颅内注射。

主要发现

  • 在具有高水平平足蛋白表达的肿瘤细胞中定义了一种恶性基因特征。
  • 在连续移植和低平足蛋白分选的胶质母细胞瘤细胞生长过程中,高平足蛋白表达的增加和/或维持表明高平足蛋白表达与不良预后相关。
  • 在对照肿瘤和平足蛋白敲除肿瘤中观察到相似的增殖、凋亡、血管生成和侵袭率。
  • 平足蛋白缺失后,肿瘤生长和生存均未受影响。

临床怎么用

  • 作者提出平足蛋白可作为预后不良的生物标志物。
  • 作者认为阻断平足蛋白并非有前景的治疗方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment options of glioblastoma, the most aggressive primary brain tumor with frequent relapses and high mortality, are still very limited, urgently calling for novel therapeutic targets. Expression of the glycoprotein podoplanin correlates with poor prognosis in various cancer entities, including glioblastoma. Furthermore, podoplanin has been associated with tumor cell migration and proliferation in vitro; however, experimental data on its function in gliomagenesis in vivo are still missing. Hence, we have functionally investigated the impact of podoplanin on glioblastoma in a preclinical mouse model to evaluate its potential as a therapeutic target. METHODS: Fluorescence activated cell sorting, genome-wide expression analysis, and clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated nuclease 9 (Cas9)-mediated deletion of podoplanin in patient-derived human glioblastoma cells were combined with organotypic brain slice cultures and intracranial injections into mice. RESULTS: We defined a malignant gene signature in tumor cells with high podoplanin expression. The increase and/or maintenance of high podoplanin expression in serial transplantations and in podoplaninlow-sorted glioblastoma cells during outgrowth indicated the association of high podoplanin expression and poor outcome. Unexpectedly, similar rates of proliferation, apoptosis, angiogenesis, and invasion were observed in control and podoplanin-deleted tumors. Accordingly, neither tumor growth nor survival was affected upon podoplanin loss. CONCLUSION: We report that tumor progression occurs independently of podoplanin. Thus, in contrast to previous suggestions, blocking of podoplanin does not represent a promising therapeutic approach. However, as podoplanin is associated with tumor aggressiveness and progression, we propose the cell surface protein as a biomarker for poor prognosis.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Eisemann T, Costa B, Harter PN, et al. Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma. Neuro Oncol. 2019. PMID: 30418623. doi:10.1093/neuonc/noy184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。